CN113101378B - Cosmetic allergen detection method and allergen patch kit - Google Patents
Cosmetic allergen detection method and allergen patch kit Download PDFInfo
- Publication number
- CN113101378B CN113101378B CN202110393608.5A CN202110393608A CN113101378B CN 113101378 B CN113101378 B CN 113101378B CN 202110393608 A CN202110393608 A CN 202110393608A CN 113101378 B CN113101378 B CN 113101378B
- Authority
- CN
- China
- Prior art keywords
- patch
- skin
- allergen
- spot
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a detection method of cosmetic allergens and an allergen patch kit, wherein the detection method comprises the following steps: a) placing cosmetics to be detected in a spot patch reagent box, wherein the cosmetics to be detected comprise sensitizers such as spices, preservatives and phenylenediamine; the patch components in the patch kit comprise the following components in percentage by mass: 1% -90% of a substrate; 1-30% of absorption promoter; 0-70% of solvent; 0.1-1% of buffer solution; b) cleaning the skin at the checkpoint area; c) coating the spot patch kit loaded with the sample solution obtained in the step a on the skin of the cleaned spot area in the step b; d) acquiring and analyzing a digital image of the skin after the patch treatment; the invention has simple operation, short detection time, higher sensitivity and accuracy, does not pollute clothes when being removed, and is more suitable for the personalized application of beauty-seeking people in screening cosmetics.
Description
Technical Field
The invention belongs to the technical field of compound detection, and mainly relates to a cosmetic allergen detection method and an allergen patch kit.
Background
Allergic Contact Dermatitis (ACD), a cell-mediated hypersensitivity reaction caused by contact with allergens, is the most clinically common category of Contact Dermatitis (CD). Allergic contact dermatitis is a typical type IV hypersensitivity reaction, and the contact is a sensitizing factor. The contact substance can be used as an antigen to initiate an immune response at the skin contact site. When the hapten is contacted again, the latent period from the contact to the appearance of the rash is shortened compared with that of the 1 st time, and at the moment, the sensitizing factor still needs to form the hapten firstly, and the sensitizing factor acts on the specifically sensitized T lymphocyte, so that obvious inflammatory reaction is generated within 24-48 hours generally. The common clinical symptoms comprise pruritus, edema, erythema, blister, bulla and the like. The treatment principle of the disease is to search the etiology, quickly separate from the contact object and actively treat the disease, and the contact with the allergen again should be avoided as much as possible after the disease is cured so as to avoid relapse. Along with the improvement of living standard of people, cosmetics are more widely applied, ACD (acute coronary disease) caused by cosmetic allergy tends to rise year by year, and related reports prove that the three first-class components of cosmetic allergy sequentially comprise perfume (33.7%), preservative (30.3%) and phenylenediamine (25.8%).
The Patch Test (Patch Test) can effectively assist in completing clinical analysis of contact dermatitis caused by cosmetic allergens, and meanwhile, studies show that diagnosis of allergens, informing of beauty demanders how to avoid contact and symptomatic treatment through the Patch Test have very obvious benefits. The patch test is a simple and reliable method for determining the allergen of a contact allergic patient. When a patient is allergic by contacting skin or mucosa with an allergen, a change in skin inflammation occurs at the contact site, i.e., allergic contact dermatitis, at any site where the same allergen or a substance having a similar chemical structure and the same antigenicity is in contact with the body surface. The patch test is based on the principle that suspected allergens are artificially configured to a certain concentration, placed at a special detection point and applied to the body surface of a human body, and whether a test object is an allergen or not is determined according to the existence of a positive reaction after a certain time. The patch test avoids traumatic operations such as acupuncture and blood drawing of patients, causes no pain to the patients, does not need expensive detection equipment, and is not only beneficial to determining cosmetic allergens but also beneficial to guiding the prevention and treatment of beauty seeking persons.
At present, the main screening methods aiming at the cosmetic allergen components comprise liquid chromatography, gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, but the screening process of the traditional screening method is too complicated, the existing spot-pasting diagnosis technology uses vaseline as an allergen detection matrix, the vaseline is hardly dissolved with other chemical substances, the vaseline is not easily mixed with the antigen of a cosmetic sample and is not easily mixed uniformly, the situation of uneven antigen distribution is easy to occur, the accuracy of the detection result is influenced, the response time of the skin allergy of the traditional spot-pasting method is long, and the result can be observed within 48 to 72 hours generally, so the diagnosis and treatment time of an applicant is delayed to a certain extent, in addition, in the skin spot-pasting test, when skin cells contact with a large amount of exogenous substances, the physiological equilibrium relationship of the skin cells is influenced and changed, further, the metabolism is abnormal, the osmotic pressure is changed (cell swelling or contraction), a series of stress reactions are generated, and diagnosis interference is caused, so that the potassium ions in human cells and the sodium ions outside the cells are required to be coordinated with each other in the test process, and the physiological functions of body fluid and tissue cells are required to be maintained. Therefore, a quick, accurate, convenient and safe personalized cosmetic screening method is urgently needed to be established.
Disclosure of Invention
The invention provides a cosmetic allergen detection method and an allergen patch kit, and mainly aims to overcome the defects of complexity, low sensitivity, long detection time, skin irritation and inaccurate detection result of the conventional cosmetic allergen screening method.
In order to solve the technical problems, the invention adopts the following technical scheme:
a) placing cosmetics to be detected in a spot patch reagent box, wherein the cosmetics to be detected comprise sensitizers such as spices, preservatives and phenylenediamine; the patch components in the patch kit comprise the following components in percentage by mass:
1% -90% of a substrate;
1-30% of absorption promoter;
0 to 70 percent of solvent
0.1-1% of buffer solution;
b) cleaning the skin at the checkpoint area;
c) coating the spot patch kit loaded with the sample solution obtained in the step a on the skin of the cleaned spot area in the step b;
d) acquiring and analyzing a digital image of the skin after the patch treatment;
further, the perfume allergen is limonene, benzyl alcohol, linalool, citronellol, geraniol, hydroxycitronellal, eugenol, isoeugenol, alpha-isomethylionone, lily of the valley aldehyde, lyral, hexyl cinnamaldehyde, benzyl benzoate, benzyl salicylate, benzyl cinnamate, amyl cinnamaldehyde, cinnamyl alcohol citral, cinnamaldehyde, coumarin;
further, the preservative allergen is methylisothiazolinone, methylchloroisothiazolinone, diazolidinyl urea, methylparaben, ethylparaben, isopropylparaben, propylparaben, isobutylparaben, butylparaben, salicylic acid, benzoic acid, sorbic acid;
further, the allergen is methylisothiazolinone, methylchloroisothiazolinone;
further, the hair dye component allergen may be resorcinol, toluene-2, 5-diamine sulfate, p-phenylenediamine, p-aminophenol, m-aminophenol, 2-amino-3-hydroxypyridine, 4-chlororesorcinol, 4-amino-2-hydroxytoluene, 2, 4-diaminophenoxyethanol hydrochloride, N-bis (2-hydroxyethyl) p-phenylenediamine sulfate, 2-chlorop-phenylenediamine sulfate, 2-methylresorcinol, 6-amino-m-cresol, phenylmethylpyrazolone, 4-amino-3-nitrophenol, 4-amino-m-cresol, p-methylaminophenol sulfate, 4-nitrophthaldiamine, 2, 6-diaminopyridine, 6-hydroxyindole, 2, 7-naphthalenediol, 2, 6-naphthalenediol, p-aminophenol sulfate, 4-nitrophthalenediamine, 2, 6-diaminopyridine, p-hydroxyindole, p-2, 7-naphthalenediol, p-aminophenol, p-phenoxyethanol hydrochloride, p-m-cresol, p-bis (2-amino-2-m-hydroxy-cresol, 2-amino-m-cresol, 2-amino-2-p-bis (2-amino-cresol, 4-amino-cresol, 2-p-bis (2-amino-hydroxy-cresol, p-bis (p-hydroxy-p-cresol), p-cresol, p-phenylene-phenylenediamine, p-phenylenediamine, p-cresol, p-phenylenediamine, p-cresol, p-cresol, p-cresol, p-cresol, p-cresol, p-cresol, p-cresol, N-phenyl-p-phenylenediamine, 1, 5-naphthalenediol or 1-naphthol;
further, the substrate comprises: one or more of polyvinylpyrrolidone, carbomer, methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, sodium polyacrylate, tragacanth, polyethylene glycol, xanthan gum, gelatin, starch, sodium alginate, and chitosan;
further, the absorption promoting agent comprises: one or more of glycerol, propylene glycol, sorbitol, 1-n-dodecane azepine cycloheptan-2-one, menthol and borneol; the mechanism of the absorption enhancer of the invention for enhancing the transdermal absorption of the antigen is as follows: acts on lipid between epidermal stratum corneum cells to loosen stratum corneum cells and increase the cell spacing, thereby causing the outer cells of the stratum corneum to easily fall off and the stratum corneum of the skin to be thinned, greatly reducing the barrier effect of the skin on medicaments, and promoting the percutaneous permeation of antigens. The kit is used together with a body temperature liquefaction combined matrix, so that the effect of mutual promotion is achieved, the detection time is greatly shortened, and the detection sensitivity is effectively enhanced;
further, the solvent comprises one or more of acetone, ethanol and water;
further, the buffer solution comprises one or more of sodium chloride, potassium dihydrogen phosphate and disodium hydrogen phosphate; the buffer solution composition can effectively overcome diagnosis interference factors caused by skin stress reaction, achieves the aim of maintaining the internal and external osmotic pressure balance of cells at a detected position and normal physiological function and metabolic function thereof during a patch test, is also beneficial to the delivery of allergen antigen substances, and further promotes the absorption of detection substances;
compared with the prior art, the invention has the beneficial effects that:
1. the method is simple and convenient to operate, short in detection time, more objective and higher in accuracy of the sensitivity and result evaluation method, does not pollute clothes when removing patches, and is more suitable for personalized application of beauty-seeking people in screening cosmetics;
2. the matrix of the invention has good water solubility, is easier to be uniformly mixed and dissolved with cosmetic samples compared with the traditional medical vaseline matrix, and has better transparency.
3. The mechanism of the absorption enhancer of the invention for enhancing the transdermal absorption of the antigen is as follows: acts on lipid between epidermal stratum corneum cells to loosen stratum corneum cells and increase the cell spacing, thereby causing the outer cells of the stratum corneum to easily fall off and the stratum corneum of the skin to be thinned, greatly reducing the barrier effect of the skin on medicaments, and promoting the percutaneous permeation of antigens. The invention is used together with the body temperature liquefaction combined matrix, achieves the effect of mutual promotion, greatly shortens the detection time and effectively enhances the detection sensitivity.
4. The cell ion buffer solution composition is added in the invention, so that the purposes of maintaining the osmotic pressure balance inside and outside cells at the detected position and normal physiological function and metabolic function of the detected position during the patch test are achieved, the diagnosis interference factors caused by skin stress reaction can be effectively overcome, meanwhile, the allergen antigen substance is also favorably conveyed, and the absorption of the detected substance is further promoted.
5. Compared with the prior art, the invention has the advantages that: the invention applies the spot pasting method matrix composition combined by the combined matrix, the absorption promoting agent, the buffer solution and the like to screen the cosmetic allergens, can change the structure of a skin barrier layer, enables the cosmetic allergens to be better mixed and permeated, improves the detection speed and the detection sensitivity of the cosmetic allergens, and provides a personalized cosmetic screening method. In addition, the buffer solution component can maintain and protect the physiological function and normal metabolism of the histiocyte of the detected part, avoid the occurrence of stress reaction, reduce exogenous diagnosis interference and ensure the accuracy of the skin allergen patch test.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and description, and is in no way intended to limit the invention.
A method for detecting cosmetic allergens is characterized by comprising the following steps:
a) placing cosmetics to be detected in a spot patch reagent box, wherein the cosmetics to be detected comprise sensitizers such as spices, preservatives and phenylenediamine; the patch components in the patch kit comprise the following components in percentage by mass:
1% -90% of a substrate;
1-30% of absorption promoter;
0 to 70 percent of solvent
0.1-1% of buffer solution;
b) cleaning the skin at the checkpoint area;
c) coating the spot patch kit loaded with the sample solution obtained in the step a on the skin of the cleaned spot area in the step b;
d) acquiring and analyzing a digital image of the skin after the patch treatment;
specifically, the spice allergen is limonene, benzyl alcohol, linalool, citronellol, geraniol, hydroxycitronellal, eugenol, isoeugenol, alpha-isomethylionone, lily of the valley aldehyde, lyral, hexyl cinnamaldehyde, benzyl benzoate, benzyl salicylate, benzyl cinnamate, amyl cinnamaldehyde, cinnamyl alcohol citral, cinnamaldehyde and coumarin.
The antiseptic allergen is methylisothiazolinone, methylchloroisothiazolinone, diazolidinyl urea, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, isopropyl p-hydroxybenzoate, propyl p-hydroxybenzoate, isobutyl p-hydroxybenzoate, butyl p-hydroxybenzoate, salicylic acid, benzoic acid, and sorbic acid.
The hair dyeing component allergen is resorcinol, toluene-2, 5-diamine sulfate, p-phenylenediamine, p-aminophenol, m-aminophenol, 2-amino-3-hydroxypyridine, 4-chlororesorcinol, 4-amino-2-hydroxytoluene, 2, 4-diaminophenoxyethanol hydrochloride, N-bis (2-hydroxyethyl) p-phenylenediamine sulfate, 2-chloro-p-phenylenediamine sulfate, 2-methylresorcinol, 6-amino-m-cresol, phenyl-methyl pyrazolone, 4-amino-3-nitrophenol, 4-amino-m-cresol, p-methyl aminophenol sulfate, 4-nitrophthaldiamine, 2, 6-diaminopyridine, 6-hydroxyindole, 2, 7-naphthalenediol, p-amino-phenoxyethanol hydrochloride, N-bis (2-hydroxyethyl) p-phenylenediamine sulfate, 2-chloro-p-phenylenediamine sulfate, 2-methylresorcinol, 6-amino-m-cresol, phenyl-methyl pyrazolone, 4-amino-3-nitrophenol, 4-amino-m-cresol, p-methyl aminophenol sulfate, 4-nitrophenol, 2, 6-diaminopyridine, 6-hydroxyindole, 2, 7-naphthalenediol, p-phenoxyethanol hydrochloride, p-phenylenediamine, m-phenylenediamine, p-cresol, and p-cresol, p-p, N-phenyl-p-phenylenediamine, 1, 5-naphthalenediol or 1-naphthol.
Specifically, the substrate comprises: one or more of polyvinylpyrrolidone, carbomer, methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, sodium polyacrylate, tragacanth, polyethylene glycol, xanthan gum, gelatin, starch, sodium alginate, and chitosan; in the patch kit, the content of the matrix in the composition in percentage by mass can be 1% -90%, preferably 25-85%, more preferably 35-80%, and further preferably 45-78%;
specifically, the absorption promoting agent comprises: one or more of glycerol, propylene glycol, sorbitol, 1-n-dodecane azepine cycloheptan-2-one, menthol and borneol; and the contents of the components in percentage by mass are respectively as follows: 25-30% (preferably 30%) of 1-n-dodecane azepin-2-one, 25-28% (preferably 30%) of propylene glycol, 20-30% (preferably 28%) of menthol and 25-30% (preferably 30%) of borneol;
the mass ratio of sodium chloride, potassium dihydrogen phosphate and disodium hydrogen phosphate in the buffer solution is 14:1: 20.
Example one
Step one, 300 ACD volunteers are selected;
step two, coating 100 parts of the prepared spot-pasting kit with different concentrations (comprising methylisothiazolinone: 0.01%, 0.02% and 0.03%) on the skin of the tested area of the left forearm of the volunteer respectively;
the left forearm patch kit comprises the following components in percentage by mass:
600075% of polyethylene glycol; 1% of xanthan gum; 1% of sodium alginate;
20% of glycerol;
0.6 percent of buffer solution (the mass ratio of sodium chloride to potassium dihydrogen phosphate to disodium hydrogen phosphate is 14:1: 20); the balance of water
Step three, preparing a common patch control sample, wherein the preparation method comprises the following steps: adding 2% of glycerol and 1% of acrylic resin, heating to 65 ℃, regulating the pH value to 6, stirring, adding 100 parts of methylisothiazolinone (0.01%, 0.02% and 0.03%) respectively, adding into a common patch small groove one by one, forming, and respectively coating the skin of a tested area of the right forearm of a volunteer;
and step four, shooting pictures of the skin of the tested area, namely the left forearm (testing group) and the right forearm (comparison group) by using a TiVi700 polarization spectrum camera, observing whether the skin of the tested area has obvious changes (red swelling, itching, infiltration, pimple, blister anaphylactic reaction and the like) at the same time, and then observing and shooting the pictures every other hour.
Note that: the patch test is not easy to be performed in the acute stage of dermatitis, and the patch test should be performed after the dermatitis is completely removed for two weeks. The subject must be instructed to remove the plaque test substance at any time, if a strong reaction occurs. Patients were not taking oral corticosteroid hormone (prednisone 15 mg/day inhibits the patch test response) for the first two weeks and periods of testing, and should be withheld from antihistamines for the first two days and periods of testing. It is not suitable for bathing, drinking and scratching the spot during spot-testing. The spot test substance should be kept on the skin for 48 hours, the spot test substance should not be removed too early as far as possible, the test part should be marked, and the tape should be sealed to avoid false positive results. If necessary (e.g., those who are highly suspected of being allergic to the allergen and negative for 72 hours), a third observation or trial repeat is performed on the seventh day after patch application. While the patch is screened, the patch test should not be ignored for suspected desensitizing substances that the patient actually contacts.
Positive rate ═ 100% (number of weak positive cases + number of strong positive cases + number of very strong positive cases)/number of test cases%
By adopting the allergen patch kit and the screening method, the positive rates of methylisothiazolinone, 0.01 percent, 0.02 percent and 0.03 percent of patches are respectively 54 percent, 73 percent and 82 percent, and the positive rates of weak and uneven erythema in a control group are respectively 13 percent, 26 percent and 34 percent.
The test group ACD patients have a positive rate obviously higher than that of the test group obtained by the common patch box and the test method, which shows that the method is more sensitive than the traditional method; the patch box is safe and reliable for ACD patients.
Example two
Step one, 300 ACD volunteers are selected;
step two, coating 100 parts of prepared patch kits with different concentrations (containing 0.1 percent, 0.2 percent and 0.3 percent of methylchloroisothiazolinone) on the skin of the tested area of the left forearm of the volunteer respectively;
the spot-pasting kit comprises the following components in percentage by mass:
45% of gelatin; 1% of carbomer; 1% of tragacanth;
10% of propylene glycol; 10% of glycerol;
0.6 percent of buffer solution (the mass ratio of sodium chloride to potassium dihydrogen phosphate to disodium hydrogen phosphate is 14:1: 20); the balance of water
Step three, preparing a common patch control sample, wherein the preparation method comprises the following steps: soaking water and aristoflex AVC 1% for swelling, dispersing, adding 3% of pentanediol, stirring uniformly, adjusting the pH to 6, adding 6% of polyurethane, stirring uniformly, adding 100 parts of methylisothiazolinone (0.01%, 0.02% and 0.03%) respectively, adding into a common patch small groove one by one, forming, and respectively coating the skin of a tested area of the right forearm of a volunteer;
and step four, shooting pictures of the skin of the tested area, namely the left forearm (testing group) and the right forearm (comparison group) by using a TiVi700 polarization spectrum camera, observing whether the skin of the tested area has obvious changes (red swelling, itching, infiltration, pimple, blister anaphylactic reaction and the like) at the same time, and then observing and shooting the pictures every other hour.
Note that the same thing as in the first embodiment is used.
Positive rate ═ 100% (number of weak positive cases + number of strong positive cases + number of very strong positive cases)/number of test cases%
The positive rates of the methylchloroisothiazolinone, 0.1%, 0.2% and 0.3% patch, respectively 55%, 76% and 88% and the positive rates of the control group, respectively 15%, 26% and 38% are obtained by screening by adopting the allergen patch kit and the screening method.
The test group ACD patients have higher positive rate to the test group than the results obtained by the common patch box and the test method, which shows that the method of the invention is more sensitive than the traditional method, and the patch box of the invention is safe and reliable to the ACD patients.
EXAMPLE III
Step one, selecting 100 ACD volunteers;
step two, coating the prepared spot pasting kit containing 1% of cinnamaldehyde on the skin of the tested area of the left forearm of the volunteer; the spot-pasting kit comprises the following components in percentage by mass:
60% of polyvinylpyrrolidone; 1% of xanthan gum; 1% of sodium alginate; 1% of chitosan;
28% of menthol;
0.5 percent of buffer solution (the mass ratio of sodium chloride to potassium dihydrogen phosphate to disodium hydrogen phosphate is 14:1: 20); the balance of water
Note that the same thing as in the first embodiment is used.
Step three, preparing a common patch control sample, wherein the preparation method comprises the following steps: soaking and swelling 1% of water and acrylic resin cross-linked polymer, dispersing, adding 3% of pentanediol, uniformly stirring, adjusting the pH to 6, adding 5% of gum arabic, uniformly stirring, adding 1% of cinnamaldehyde, adding into a common patch small groove one by one, molding, and respectively coating the skin of a tested area of the right forearm of a volunteer;
and step four, shooting pictures of the skin of the tested area, namely the left forearm (testing group) and the right forearm (comparison group) by using a TiVi700 polarization spectrum camera, observing whether the skin of the tested area has obvious changes (red swelling, itching, infiltration, pimple, blister anaphylactic reaction and the like) at the same time, and then observing and shooting the pictures every other hour.
Positive rate ═ 100% (number of weak positive cases + number of strong positive cases + number of very strong positive cases)/number of test cases%
The positive rates of the patches of 1% cinnamaldehyde obtained by screening by adopting the allergen patch kit and the screening method are respectively 75%, and the positive rate of a control group is 30%.
Example four
Step one, selecting 100 ACD volunteers;
step two, respectively coating the prepared spot-pasting kit containing 2.5% of coumarin on the skin of the tested area of the left forearm of the volunteer, wherein the spot-pasting kit comprises the following components in percentage by mass:
60% of sodium carboxymethyl cellulose; 1% of xanthan gum;
30% of 1-n-dodecaneazepin-2-one;
0.5 percent of buffer solution (the mass ratio of sodium chloride to potassium dihydrogen phosphate to disodium hydrogen phosphate is 14:1: 20); the balance of water
Note that the same applies to the first embodiment;
step three, preparing a common patch control sample, wherein the preparation method comprises the following steps: soaking and swelling water and 2% of acrylic resin cross-linked polymer, dispersing, adding 4% of pentanediol, uniformly stirring, adjusting the pH to 6, adding 5% of polyurethane, uniformly stirring, adding 2.5% of coumarin, adding the mixture into a common patch small groove one by one, forming, and respectively coating the mixture on the skin of a tested area of the right forearm of a volunteer;
step four, shooting pictures of the skin of a tested area, namely a left forearm (a test group) and a right forearm (a control group) by using a TiVi700 polarization spectrum camera, simultaneously observing whether the skin of the tested area has obvious changes (red swelling, itching, infiltration, pimple, blister anaphylactic reaction and the like), and then observing and shooting the pictures every other hour;
positive rate ═ 100% (number of weak positive cases + number of strong positive cases + number of very strong positive cases)/number of test cases%
The positive rates of 2.5% of the coumarin patches obtained by screening by adopting the allergen patch kit and the screening method are 77% respectively, and the positive rates of a control group are 30%. The test group ACD patients have higher positive rate than the test group by the common patch box and the test method, which shows that the method of the invention is more sensitive, safer and more reliable than the traditional method.
EXAMPLE five
Step one, selecting 100 ACD volunteers;
step two, coating the prepared spot pasting kit containing phenylenediamine 1% on the skin of the tested area of the left forearm of the volunteer, wherein the spot pasting kit comprises the following components in percentage by mass:
50% of hydroxypropyl methyl cellulose; 1% of carbomer;
28% of propylene glycol;
0.5 percent of buffer solution (the mass ratio of sodium chloride to potassium dihydrogen phosphate to disodium hydrogen phosphate is 14:1: 20); the balance of water
Note that the same thing as in the first embodiment is used.
Step three, preparing a common patch control sample, wherein the preparation method comprises the following steps: uniformly mixing water with 2% of glycerol and 5% of hydroxypropyl distarch phosphate, adjusting the pH to 6, uniformly stirring, adding 1% of phenylenediamine, adding the phenylenediamine into common small patches and grooves one by one, forming, and respectively coating the small patches and the small grooves on the skin of a tested area of the right forearm of a volunteer;
and step four, shooting pictures of the skin of the tested area, namely the left forearm (testing group) and the right forearm (comparison group) by using a TiVi700 polarization spectrum camera, observing whether the skin of the tested area has obvious changes (red swelling, itching, infiltration, pimple, blister anaphylactic reaction and the like) at the same time, and then observing and shooting the pictures every other hour.
Positive rate ═ 100% (number of weak positive cases + number of strong positive cases + number of very strong positive cases)/number of test cases%
The positive rates of the phenylenediamine spot patches 1% and the control group are respectively 76% and 27% respectively, which are obtained by screening through the allergen spot patch kit and the screening method.
The test group ACD patients have higher positive rate than the test group by the common patch box and the test method, which shows that the method of the invention is more sensitive, safer and more reliable than the traditional method.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (2)
1. The application of a composition in preparing a patch reagent for specifically detecting methylisothiazolinone is characterized in that the composition comprises the following components in percentage by mass:
600075% of polyethylene glycol; 1% of xanthan gum; 1% of sodium alginate; 20% of glycerol; 0.6% of buffer solution; the balance of water;
the buffer solution is prepared from sodium chloride: potassium dihydrogen phosphate: the disodium hydrogen phosphate is prepared according to the mass ratio of 14:1: 20.
2. The application of a composition in preparing a patch reagent for specifically detecting methylchloroisothiazolinone, wherein the composition comprises the following components in percentage by mass:
45% of gelatin; 1% of carbomer; 1% of tragacanth; 10% of propylene glycol; 10% of glycerol; 0.6% of buffer solution; the balance of water; the buffer solution is prepared from sodium chloride: potassium dihydrogen phosphate: the disodium hydrogen phosphate is prepared according to the mass ratio of 14:1: 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393608.5A CN113101378B (en) | 2021-04-13 | 2021-04-13 | Cosmetic allergen detection method and allergen patch kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110393608.5A CN113101378B (en) | 2021-04-13 | 2021-04-13 | Cosmetic allergen detection method and allergen patch kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113101378A CN113101378A (en) | 2021-07-13 |
| CN113101378B true CN113101378B (en) | 2021-11-16 |
Family
ID=76716283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110393608.5A Active CN113101378B (en) | 2021-04-13 | 2021-04-13 | Cosmetic allergen detection method and allergen patch kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113101378B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113848099A (en) * | 2021-09-03 | 2021-12-28 | 三立慧评(北京)检测技术有限公司 | Matrix composition for evaluating safety of cosmetic raw materials and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102380107A (en) * | 2011-10-18 | 2012-03-21 | 中国人民解放军第三军医大学第一附属医院 | Method for detecting whether patient is allergic to medicine |
| CN112294975A (en) * | 2019-07-26 | 2021-02-02 | 上海市皮肤病医院 | Contact allergen reagent combination and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106267245A (en) * | 2016-09-23 | 2017-01-04 | 何韶衡 | A kind of gel combination, patch and preparation method thereof |
| CN106924760B (en) * | 2017-03-29 | 2020-08-21 | 三明市和众生物技术有限公司 | Diagnostic matrix composition for skin allergen patch test and preparation method thereof |
| CN110018161B (en) * | 2019-02-28 | 2022-05-20 | 北京三立慧评化妆品科技有限公司 | Method for detecting irritation of cosmetic raw material and method for detecting irritation resistance of irritation-resistant product |
| CN110174488B (en) * | 2019-06-10 | 2021-08-24 | 青岛农业大学 | Method for detecting allergen in cosmetics |
| CN211970207U (en) * | 2020-04-26 | 2020-11-20 | 绍兴美迪康生物技术有限公司 | Fixable allergen detection kit |
-
2021
- 2021-04-13 CN CN202110393608.5A patent/CN113101378B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102380107A (en) * | 2011-10-18 | 2012-03-21 | 中国人民解放军第三军医大学第一附属医院 | Method for detecting whether patient is allergic to medicine |
| CN112294975A (en) * | 2019-07-26 | 2021-02-02 | 上海市皮肤病医院 | Contact allergen reagent combination and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| "Predictive values for skin prick test and atopy patch test for eosinophilic esophagitis";JM Spergel等;《J ALLERGY CLIN IMMUNOL》;20071231;第119卷(第2期);第509-511页 * |
| "慢性湿疹和皮炎122例斑贴试验结果分析";朱国兴等;《临床皮肤科杂志》;20060227;第35卷(第2期);第81-83页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113101378A (en) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shiva et al. | Formulation and evaluation of topical antifungal gel of fluconazole using aloe vera gel | |
| HUE030028T2 (en) | Antifungal pharmaceutical composition | |
| JPH06211651A (en) | Composition for treating nail trichophytosis | |
| CN113101378B (en) | Cosmetic allergen detection method and allergen patch kit | |
| CN103919967A (en) | Dracaena cochinchinensis resin compound and application thereof in preparation of medicines for treating trauma | |
| JPH07206711A (en) | Composition for treatment of trichophytosis unguium | |
| JP6420258B2 (en) | Topical antifungal composition for treating onychomycosis | |
| CN109172518B (en) | External preparation containing vitamin K1 and preparation method thereof | |
| CN105687207A (en) | Ointment for treating dermatitis and eczema and preparation method thereof | |
| CN106668004A (en) | Edaravone and (+)2-camphol liniment and preparation method thereof | |
| CN105030716B (en) | Caffeinum pharmaceutical combination and preparation method thereof | |
| CN104706570B (en) | A kind of Halometasone Cream and preparation method thereof | |
| Azagury et al. | A novel approach for noninvasive drug delivery and sensing through the amniotic sac | |
| CN112294975A (en) | Contact allergen reagent combination and application thereof | |
| CN114601789B (en) | Celecoxib gel and preparation method and application thereof | |
| Belango et al. | Anti-inflammatory property of the formulated topical gel from the crude leaf extracts of Sampaguita (Jasminum sambac L. family: Oleaceae) | |
| Patil et al. | Development and evaluation of transdermal gel of acyclovir using Nerolidol as penetration enhancer | |
| JP2951725B2 (en) | Topical composition for tinea unguium | |
| US20220280464A1 (en) | Effects of Heparin on Topical Use of Plasters Containing a Non-Steroidal Anti-Inflammatory Drug | |
| EP4140476A1 (en) | An oil-in-water emulsion gel comprising tiotropium bromide | |
| CN115212214A (en) | Naftifine ketoconazole cream composition and preparation method thereof | |
| KR20160121538A (en) | Topical antifungal composition for treating onychomycosis | |
| DAS et al. | Formulation Of Quercetin Ointment For The Management Of Psoriasis. | |
| CN116999359A (en) | Anti-hair loss stock solution containing transdermal recombinant collagen and preparation method thereof | |
| JP2021527634A (en) | Topical formulations of DGAT1 inhibitors and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |